A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Completed

Conditions studied: Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

In brief

The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. The enrollment period will last for two years from the first treatment following product approval (through 31March2020) and include a minimum of 40 patients.

Key facts

Study ID
NCT03597399
Run by
Spark Therapeutics, Inc.
People needed
87
Starts
2019-01-10
Expected to finish
2025-06-30
Last updated by the study team
2025-09-22

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.